Description of Insulin Resistance in Patients With Chronic Heart Failure
1 other identifier
observational
80
1 country
1
Brief Summary
The purpose of this study is to describe insulin resistance in a general chronic heart failure population, in combination with muscle strength, body composition and cardiac function. It is assumed that insulin resistance is increased in CHF patient, and that this is related to decreased muscle strength and decreased lean tissue mass.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started May 2011
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2013
CompletedFirst Submitted
Initial submission to the registry
December 8, 2013
CompletedFirst Posted
Study publicly available on registry
December 17, 2013
CompletedDecember 17, 2013
December 1, 2013
1.6 years
December 8, 2013
December 11, 2013
Conditions
Outcome Measures
Primary Outcomes (1)
Glucose tolerance
glucose and insulin concentration measurements in blood during oral glucose tolerance test
day1
Secondary Outcomes (5)
HbA1c, blood lipids, BNP
day 1
Muscle strength: maximal strength tested on a isokinetic dynamometer
Day 1
Body composition: dual energy x-ray absorptiometry
Day 1
cardiac function: echocardiography, retrospective from hospital files
retrospective
Health-related quality of life: MLHFQ and Eq5d
Day 1
Study Arms (2)
Patients with chronic heart failure
other
Healthy volontiers
other
Eligibility Criteria
patients with chronic heart failure
You may qualify if:
- diagnosis of chronic heart failure for at least 6 months,
- clinically stable (not hospitalized) for more than 3 months prior to the onset of the study,
You may not qualify if:
- glucose lowering medical therapy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hasselt University
Hasselt, Limburg, 3500, Belgium
Study Officials
- PRINCIPAL INVESTIGATOR
Bert Op 't Eijnde, prof. dr.
Hasselt University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- prof. dr.
Study Record Dates
First Submitted
December 8, 2013
First Posted
December 17, 2013
Study Start
May 1, 2011
Primary Completion
December 1, 2012
Study Completion
December 1, 2013
Last Updated
December 17, 2013
Record last verified: 2013-12